Chinese Biosimilar Boom Is Heralded By First Approval
Executive Summary
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
You may also be interested in...
Henlius Delivers On Innovation Agenda In 2021
Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.
Henlius Wins Chinese Approval For Rituximab RA Indication
Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.
Henlius CEO Wenjie Zhang Takes Over Chairman Role
Henlius has reshuffled its C-suite, with chairman Qiyu Chen stepping down from the role to take up a position as non-executive director and CEO Wenjie Zhang poised to step into his shoes.